Want to see TSE:MGRO full AI Analyst Report?
MGRO Stock Chart & Stats
C$0.36
-C$0.02(-4.17%)
At close: 4:00 PM EDT
C$0.36
-C$0.02(-4.17%)
Day’s Range― - ―
52-Week RangeC$0.29 - C$0.94
Previous CloseN/A
Volume3.80K
Average Volume (3M)27.52K
Market Cap
C$20.15M
Enterprise ValueC$32.96
Total Cash (Recent Filing)C$419.58K
Total Debt (Recent Filing)C$553.41K
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding62,959,820
10 Day Avg. Volume43,344
30 Day Avg. Volume27,516
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)C$25.00M
Bulls Say, Bears Say
Bulls Say
Asset-light Licensing ModelMustGrow's business model focuses on licensing its biologic IP and collecting milestones/royalties rather than building a direct sales network. That structural model reduces capital intensity, lets the company focus R&D and regulatory effort, and leverages partners' manufacturing and distribution over the medium term.
Moderate Leverage ProfileReported debt roughly two-thirds of equity indicates leverage is not extreme. With manageable absolute debt levels, MustGrow has more financial flexibility to fund regulatory work or partner deals than a highly leveraged peer, lowering immediate solvency pressure as it pursues commercialization.
Demonstrated Historical Revenue ScaleThe company previously attained multi-million dollar revenue runs (~$8.3M in 2025), showing that its products or partner arrangements can generate meaningful sales. That prior commercial traction is a durable indicator of market relevance and suggests upside if regulatory validation and partner execution improve.
Bears Say
Sharp, Volatile Revenue DeclineA nearly 44% TTM revenue drop and year-to-year volatility undermine stable growth. Persistent top-line decline weakens predictability of royalties/milestones, complicates multi-period planning and partner confidence, and raises the risk that scale economies and margin improvements will not materialize without corrective actions.
Chronic Negative Cash GenerationConsistent negative operating and free cash flow indicate the business consumes capital to operate and develop products. This ongoing cash burn reduces runway and increases reliance on external financing or dilutive raises, potentially slowing development or commercialization if partner payments or new funding do not materialize.
Large Losses And Equity ErosionDeep operating and net losses and a collapse in reported equity signal sustained unprofitability and weakened balance sheet resilience. Very negative returns on equity limit internal capacity to absorb setbacks or scale operations, increasing long-term financing risk and the possibility of dilution to support growth.
MustGrow Biologics News
MGRO FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was C$0.29 and its highest was C$0.94 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is C$20.15M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 11 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 62,959,820 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in TSE:MGRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
MGRO Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―